Inspire Medical Systems

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Inspire Medical Systems sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 4 currently recruiting 2 completed later-stage tilt upper quartile by trial count

Inspire Medical Systems: 8 sponsored US clinical trials, 4 recruiting.

Inspire Medical Systems sponsors 8 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 2 completed. 2 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obstructive Sleep Apnea, with 3 trials.

Upper-quartile sponsor footprint

Inspire Medical Systems sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Where Inspire Medical Systems enrollment is open (later-stage tilt)

4 recruiting of 8 indexed (50% open); 2 completed (25%).

Phase mix: 2 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Obstructive Sleep Apnea (3 trials), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Inspire Medical Systems: open-pipeline peers nationwide

Peers matched on 8 registered trials and 50% open enrollment, not the therapeutic-area sidebar.

Inspire Medical Systems sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-07-11 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0246810 0%20%40%60% Total trials Recruiting share Inspire Medical SystemsAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)1200 Pharma1ST Biotherapeutics3ive Labs60 Degrees Pharmaceuticals
Inspire Medical Systems sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-07-11 snapshot).

Inspire Medical Systems sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 50% open enrollment (± trial volume)

What to do with this Inspire Medical Systems page

8 registered trials is a research-attention snapshot, not an endorsement of Inspire Medical Systems or any single study.

  • 4 of Inspire Medical Systems's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obstructive Sleep Apnea is the condition Inspire Medical Systems studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obstructive Sleep Apnea trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Inspire Medical Systems pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.